Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rupatifen fumarate is a small molecule dual antagonist of the histamine H1 receptor and the platelet-activating factor (PAF) receptor. Developed by Fujian Mindong Rejuvenation Pharmaceutical, it is currently in Phase 3 clinical development for the treatment of seasonal allergic rhinitis. The drug is designed to inhibit the inflammatory pathways associated with both the early-phase (histamine-mediated) and late-phase (PAF-mediated) allergic responses, which contribute to symptoms such as sneezing, nasal itching, and congestion. In clinical trials, it is typically administered as an oral capsule and has been evaluated in head-to-head studies against rupatadine fumarate, a structurally related antihistamine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on rupatifen fumarate.